Background:To improve healthcare quality, a preventive intervention system has been developed globally with routine newborn screening, diagnosis, intervention, and rehabilitation for congenital hearing impairment. An intervention program with Newborn Hearing Screening (NHS) was implemented in Guangdong Province, China, in 1999, along with molecular screening for common inherited deafness mutations since 2011. Methods: We evaluated the clinical screening data for congenital hearing impairment and the results of genetic testing for deafness genes that were collected by the Guangdong provincial administrative agencies and stored in the provincial healthcare intervention system. Results: NHS rates varied from <30% in eastern Guangdong to >95% in the provincial capitol. This difference in rates correlated primarily with the regional per capita Gross Domestic Product (GDP; R 2 =0.69, p<.001) and the average maternal hospitalization days (R 2 =0.11, p=.01). The province-wide screening rate increased from 30.0% in 2008 to 80.58% in 2016. Combined screening for hearing and deafness genes was conducted in several hospitals in developed regions. The total mutation rate of hearing and deafness genes ranged from 3.08% to 4.5%, with GJB2 235 del C being the most frequently encountered mutation. Three hospitals conducted genetic screening of pregnant women for hearing and deafness genes, and the rate of mutation carrier ranged from 3.16% to 4.17%. Conclusion: To further improve healthcare quality, hospitals are recommended to implement hearing screening and diagnostic procedures, networking platforms, genetic diagnostic testing, and genetic counseling services. Furthermore, there is an urgent need for more referral molecular testing laboratories to perform molecular diagnosis of hearing loss.